Simple research view

ELV · Elevance Health, Inc.

$426.79 latest stored close

Detected setup VCP

Watch · Quality 22/100

1 independent risk warning also present. Review before relying on the bullish setup.

Ask about ELV

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$ELV

Elevance Health, Inc.

Elevance Health, Inc. is a large-cap Managed Health Care company in the Health Services sector with a market cap of $93B.

Strong Buy · 91 Health Services Managed Health Care stock Stage 2 · Advancing Base 3+ Data 1h 58m ago

$426.79 latest close

⚠ Risk Signals

Bearish RSI Divergence Price higher high ($402.27→$424.43) but RSI lower high (78→72) — momentum diverging

Bearish structure on the daily chart — a heads-up for anyone holding, not a short signal. Does not affect the bullish setup score.

← Back Join to Watchlist $ELV Share card

Council read · 6 methods

Watch — evidence is building

0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.

Review six verdicts Inspect chart

Earnings-risk mode

Normal technical setup

Thursday, July 16, 2026 Time not confirmed No sourced report session or clock time

Deterministic evidence

ELV+0.38%

Same completed session window ending 2026-07-14. Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

AI interpretation (optional)

Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.

Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.

Price $426.79 Jul 14 close

52W High $436.24 -2.2%

52W Low $273.71

Wks Since High 0w

Tight Wks 1

Base B3

SMA 50 $397.61

SMA 200 $348.56

Avg Vol 1,662,317

RS Rank 69

RS vs High -1.4%

RS Slope +6.6% ▲

Grp Rank #17/64

ADR% 2.6%

ATR(14) $12.07 (2.8%)

Rel Vol (today) 1.32×

Vol Pace N/A

U/D Vol 0.54

A/D Days 18A / 11D

A/D Rating A+

VDU Bars 0/10 d

Power Trend 9d

Earnings past

$273.71

$436.24 94%

ELV Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for ELV.

Create Free Account

Setup Quality B+ 5/7 signals

Score trend

✓ Stage 2 · Advancing ✓ Power Trend 9d ✗ RS New High ✓ Trend 7/8 ✗ No Pattern ✓ CANSLIM 82.7 (B) ✓ Gatekeeper Base #3 (C)

See the full conviction stack.

Unlock Insights

Technical Analysis Report Card

$ELV · $426.79 · as of 2026-07-14 · multi-factor read

/ 100

Strong Buy

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend

Weekly ▲ Uptrend

Monthly ▲ Uptrend

Moving Averages

50-day$397.61 ↑

100-day$354.64 ↑

200-day$348.56 ↑

Bullish (50 > 200)

RSI (14)

Reading62.9 · Bullish

Bullish momentum — comfortably in buyer territory.

MACD (12/26/9)

StateBullish

Histogram+2.073

Bullish — MACD above its signal line and above zero. Histogram expanding.

Bollinger Bands (20,2)

%B / Width89% · 14.4%

Near the upper band — buyers in control.

Volume · Buyer vs Seller

Up/Down vol0.54 · Distribution

Rel volume1.32×

Distribution — volume is concentrated on down days; sellers dominate. Recent volume is easing versus its baseline.

Support & Resistance

R · $436.2452-week high

Price · $426.79now

S · $382.77swing level

S · $337.54swing level

S · $323.30swing level

Fibonacci · Uptrend swing

23.6%$398.15

38.2%$374.59

50.0%$355.54

61.8%$336.49

78.6%$309.38

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.

Unlock the exact entry, stop-loss, profit target, and reward-to-risk for ELV — plus the full 495-symbol scanner and Ask-the-Legends chat.

🔒 Start your 7-day free trial →

Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishVolume distribution

Want this read in a legend's voice? 💬 Ask a Legend about ELV

Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →

Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.

Council consensus: 🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.

Minervini

Watch

Minervini C

Trend-template read: 9/13 pass; wait for the soft misses to improve.

Passing evidence

1.1 Price > 150-day MA AND 200-day MAPrice $426.79, MA150 $353.54, MA200 $348.56

1.2 150-day MA > 200-day MAMA150 $353.54 vs MA200 $348.56

Failing evidence

1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 67

2. ROE ≥ 17%ROE 11.9%

9/13 checks

Method → Playbook → Ask →

O'Neil

Avoid

O'Neil D

CANSLIM read: fails L: RS rank ≥ 80 (IBD leadership).

Passing evidence

C: Quarterly EPS acceleration ≥ 25%+277.8% QoQ

N: Near 52-week high or RS line new high2.2% below high | RS line new high: False

Failing evidence

L: RS rank ≥ 80 (IBD leadership)RS rank 67

A: Annual earnings & revenue qualityRev +12.5% | ROE 11.9%

3/8 checks

Method → Playbook → Ask →

Weinstein

Watch

Weinstein C

Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

Passing evidence

Stage 2 (Advancing phase) confirmedStage 2 (Advancing)

Price above 30-week MA (200-day proxy)Price $426.79 vs MA200 $348.56

Failing evidence

Volume expansion above averageVolume ratio 1.32x

Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base

5/7 checks

Method → Playbook → Ask →

Livermore

Watch

Livermore B

Pivotal-point read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$426.79

Volume vs average1.32x

Failing evidence

Relative strengthRS 67

Pivotal point cleared on expanding volumeNot confirmed

4/6 checks

Method → Playbook → Ask →

Darvas

Watch

Darvas B

Box-theory read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$426.79

Volume vs average1.32x

Failing evidence

Relative strengthRS 67

Box top broken on heavy volumeNot confirmed

4/6 checks

Method → Playbook → Ask →

Wyckoff

Watch

Wyckoff B

Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.

Passing evidence

Price$426.79

Volume vs average1.32x

Failing evidence

Relative strengthRS 67

Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending

4/6 checks

Method → Playbook → Ask →

Breakout Health

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Follow-Through Tracking

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising

Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net -1 A+

Minervini · Grade Card

Fundamentals & leadership quality — Minervini SEPA criteria · 3/7 met

C 3/7 SEPA

Separate score from the 8-point Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.

✓ EPS acceleration ≥25% QoQ +278%

✗ Revenue growth ≥20% YoY +12%

✗ Gross margin ≥30% —

✗ ROE ≥17% 12%

✗ RS rating ≥80 (leadership) 67

✓ Stage 2 uptrend (Weinstein) Stage 2

✓ Within 25% of 52W high -2.2%

Method Playbook

📋 Trade it like O'Neil EXACT LEVELS · PRO

Minervini O'Neil Livermore Weinstein Darvas Wyckoff

O'Neil D · Avoid — The deterministic methodology check is Avoid; wait until the blocking criteria are resolved.

Pivot

Pro level

Published-method rule: Use the proper base pivot or handle high after CANSLIM leadership and market-direction checks are satisfied.
Evidence: Canonical setup geometry is available with Pro.

Entry trigger

Pro level

Published-method rule: Require a breakout through the pivot on volume at least 40% above average; the valid buy zone ends 5% above the pivot.
Evidence: Canonical setup geometry is available with Pro.

Initial stop

Pro level

Published-method rule: Use the setup's structural stop with a hard 7–8% maximum-loss ceiling from the actual entry.
Evidence: Canonical setup geometry is available with Pro.

Trail

Rule-based

Published-method rule: Protect progress under constructive support such as the 21-day or 10-week line; a stop may ratchet higher but never lower.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.

Exit / invalidation

Pro level

Published-method rule: Exit on the hard loss limit, a decisive support break, or a rule-based climax/distribution signal; a normal 20–25% advance is reviewed rather than assumed permanent.
Evidence: Canonical setup geometry is available with Pro.

Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →

Pattern Analysis (historical · 13d ago)

VCP ⚠ 3rd-stage base ⚠ Bearish RSI divergence

70.0 score

RS Score 67

Trend 7/8 ✓

CANSLIM 82.7* (B)

C1 10.7%

→

C2 4.7%

2 contractions 10.7% depth ✓ tightening ✓ vol dry ✓ near pivot ✓ right side Q: 88

Why This Setup? D+W Confluence

VCP

The Universal Edge Check

The panel is uneasy

Too many universals unmet — this leans closer to a guess than a trade.

1/7 universals met

In a confirmed uptrend Stage 2 · Trend 7/8
Risk is defined No stop — undefined risk
Asymmetric reward No target set
Not chasing (in range) Pivot distance unknown
Volume confirms 1.3× average — light
Clear of earnings in -12 days — event risk
A relative-strength leader RS 69 — middling

Why these seven? → The Universal Edge

Minervini Trend Template

7/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $426.79 vs SMA150 $353.54 / SMA200 $348.56

SMA 150 above SMA 200 SMA150 $353.54 vs SMA200 $348.56

SMA 200 trending up Slope +8.96 over 20 days

SMA 50 above SMA 150 & 200 SMA50 $397.61

Price above SMA 50 $426.79 vs SMA50 $397.61

30%+ above 52W low +55.9% from $273.71

Within 25% of 52W high -2.2% from $436.24

RS score above 70 RS 67

Fundamentals

52W Range

94%

Mkt Cap SEC

92.6B

EPS QoQ

+278%

Rev YoY

+12%

ROE

12%

D/E

0.73

EPS TTM

$25.21

P/E TTM

16.9x

Float

217M

Insider

No Buy

Company

Legend AI snapshot

Elevance Health, Inc.

ELV · NYSE · Health Services · Managed Health Care

$426.79latest close $92.6Bmarket cap 69RS rank 70setup score

O'Neil · Grade Card

CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market

B 82.7* CANSLIM * disqualified on M

C · Curr. EPS

100

A · Annual EPS

N · New Highs

100

S · Supply/Demand

100

L · Leader RS

I · Inst. Spons.

100

M · Market

Weekly Context

Multi-timeframe signals from weekly bars

W. Trend

8/8

W. RS

W. Support

$274.84

W. Resist

$427.64

W. Patterns

Base Breakout

Weekly Structure

Trend Neutral

Tight Weeks 1

Confirmation Neutral

Scan History

Jul 15

VCP ✓ Gate

Jul 14

VCP ✓ Gate

70 0.0%

Jul 13

VCP ✓ Gate

70 +0.4%

Jul 10

VCP ✓ Gate

70 +2.5%

Get the full picture on ELV

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.

Start 7-Day Free Trial